what is Alecensa (by AI)
Alecensa (generic name: alectinib) is a prescription medication used to treat non-small cell lung cancer (NSCLC) that is ALK-positive. It is a targeted therapy designed to inhibit the activity of the anaplastic lymphoma kinase (ALK) gene, which can drive the growth of certain types of cancer cells.
🧬 How Alecensa Works
Alecensa is a tyrosine kinase inhibitor (TKI) that specifically targets and blocks the activity of the ALK protein. In patients with ALK-positive NSCLC, this protein can promote cancer cell proliferation. By inhibiting ALK, Alecensa helps to prevent the growth and spread of cancer cells.WSJ+7Cancer Research UK+7alecensa+7
💊 Indications
Alecensa is approved for:
-
Adjuvant treatment: To help prevent the recurrence of early-stage (stage IB to IIIA) ALK-positive NSCLC after surgical tumor resection. WSJ+4Wikipedia+4alecensa+4
-
Metastatic treatment: For patients with advanced or metastatic ALK-positive NSCLC.
📋 Dosage and Administration
-
Standard dose: 600 mg taken orally twice daily with food.Medical News Today
-
Capsule form: Each capsule contains 150 mg of alectinib. Patients typically take four 150 mg capsules per dose. alecensa
-
If side effects occur, the dosage may be adjusted to 450 mg or 300 mg twice daily. Medical News Today
⚠️ Side Effects
Common side effects include:
-
Constipationalecensa+1alecensa+1
-
Tirednessalecensa
-
Swelling in hands, feet, ankles, face, or eyelidsalecensa+1Wikipedia+1
-
RashU.S. Food and Drug Administration+11Comprehensive Cancer Information+11Medical News Today+11
-
Coughalecensa
Serious side effects may include:
-
Liver damage (e.g., jaundice, nausea, dark urine)
-
Severe muscle pain or weaknessalecensa+1Medscape+1
-
Lung problems (e.g., shortness of breath, cough)
-
Heart issues (e.g., slow heart rate)
-
Low red blood cell count (anemia)
Regular monitoring of liver function and blood counts is recommended during treatment.
🧪 Testing and Monitoring
Before starting treatment, patients should undergo testing to confirm the presence of the ALK gene mutation. Regular follow-up appointments are necessary to monitor for side effects and assess treatment efficacy.
🌍 Availability and Access
Alecensa is approved in over 100 countries, including the United States, Japan, and members of the European Union. In the U.S., it is marketed by Genentech, a member of the Roche Group. WSJ
تعليقات
إرسال تعليق